| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 0.00 | 100.0% | |
| Total Income | 0.00 | 100.0% | |
| Expenditure | 47.34 | 7.0% | 0.4% |
| PBT | — | ||
| Net Profit | -44.76 | 85.3% | 4.9% |
| OPM | — | ||
| NPM | — | ||
| EPS | -1.92 | 74.5% | 33.6% |
Lyell Immunopharma Reports Q2 2026 Net Loss of $44.8 Million Amidst Clinical Progress
07 Aug 2026 · 7 Aug, 1:55 am
Summary
Lyell Immunopharma reported a net loss of $44.8 million for the second quarter ended June 30, 2026, an increase from $42.7 million in the same period last year, primarily driven by a $4.7 million rise in research and development expenses due to heightened clinical trial activity. The company's financial position remains robust with $228.0 million in cash, cash equivalents, and marketable securities, providing a projected cash runway into the third quarter of 2027. Significant clinical progress was highlighted, including the PiNACLE pivotal trial for ronde-cel remaining on track for additional data in late 2026 and a BLA submission in late 2027. Additionally, updated safety data for LYL273 showed a substantial reduction in adverse events, leading to an amendment of its U.S. Phase 1 trial to a Phase 1/2 design for potential pivotal expansion.
Key Highlights
- 1
Lyell Immunopharma reported a net loss of $44.8 million for the second quarter ended June 30, 2026, compared to a net loss of $42.7 million for the same period in 2025.
- 2
Research and development expenses increased by $4.7 million to $39.5 million in Q2 2026, primarily driven by increased clinical trial activity.
- 3
The company's cash, cash equivalents, and marketable securities totaled $228.0 million as of June 30, 2026, providing a projected runway into the third quarter of 2027.
- 4
The PiNACLE pivotal clinical trial for ronde-cel is on track to report additional data in the second half of 2026, with pivotal data expected mid-2027 and BLA submission in the second half of 2027.
- 5
Updated LYL273 safety data showed a significant reduction in Grade ≥ 2 diarrhea or colitis from 55% to 10% with a new gastrointestinal prophylaxis regimen.
- 6
The U.S. Phase 1 trial for LYL273 was amended to a Phase 1/2 design, enabling seamless expansion into a potential pivotal single-arm Phase 2 trial.
Informational and educational content only. Not investment advice.